NewsBenzinga소피아 제네틱스, 마이리어드 제네틱스와 협력해 새로운 전립선암 특이적 유전체 불안정성 점수 기술 개발 추진 소피아 제네틱스, 마이리어드 제네틱스와 협력해 새로운 전립선암 특이적 유전체 불안정성 점수 기술 개발 추진 Benzinga 2026.10.08 13:03 (GMT+0) Open on Benzinga Other news Morgan Stanley Maintains Underweight on Lazard, Lowers Price Target to $41 Wells Fargo Maintains Overweight on BlackRock, Lowers Price Target to $1230 RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345 Wells Fargo Maintains Equal-Weight on Levi Strauss, Lowers Price Target to $20 Jeff Bezos Could Take Blue Origin Public. Amazon Investors Just Got a New Space Question Morgan Stanley Maintains Overweight on Houlihan Lokey, Lowers Price Target to $165
